Compass Therapeutics (CMPX) Accounts Payables (2018 - 2026)
Compass Therapeutics recorded quarterly Accounts Payables of $906000.0 in Q1 2026, down 42.84% quarter-over-quarter from $1.6 million in Q4 2025, and down 42.55% year-over-year from $1.6 million in Q1 2025.
Compass Therapeutics' Accounts Payables history runs 9 years deep, the most recent figure standing at $906000.0 for Q1 2026.
- In Q1 2026, Accounts Payables fell 42.55% year-over-year to $906000.0; the TTM figure through Mar 2026 stood at $906000.0 (down 42.55% YoY), while the FY2025 annual figure was $1.6 million, down 29.52% from the prior year.
- Accounts Payables came in at $906000.0 for Q1 2026 at Compass Therapeutics, down from $1.6 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $6.5 million in Q2 2022 to a low of $257000.0 in Q1 2022.
- A 5-year average of $2.1 million and a median of $1.6 million in 2025 frame the typical range for Accounts Payables.
- On a YoY basis, Accounts Payables climbed as much as 337.74% in 2023 and fell as far as 88.92% in 2023.
- Compass Therapeutics' Accounts Payables stood at $3.4 million in 2022, then advanced by 20.93% to $4.1 million in 2023, then sank by 45.01% to $2.2 million in 2024, then retreated by 29.52% to $1.6 million in 2025, then slumped by 42.84% to $906000.0 in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $906000.0, $1.6 million, and $3.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 8.64 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Compass Therapeutics | 418.47 Mn | 223.78 Mn | - | 906,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 906,000.00 |
| Dec 31, 2025 | 1.59 Mn |
| Sep 30, 2025 | 3.10 Mn |
| Jun 30, 2025 | 2.60 Mn |
| Mar 31, 2025 | 1.58 Mn |
| Dec 31, 2024 | 2.25 Mn |
| Sep 30, 2024 | 960,000.00 |
| Jun 30, 2024 | 1.19 Mn |
| Mar 31, 2024 | 854,000.00 |
| Dec 31, 2023 | 4.09 Mn |
| Sep 30, 2023 | 2.31 Mn |
| Jun 30, 2023 | 724,000.00 |
| Mar 31, 2023 | 1.13 Mn |
| Dec 31, 2022 | 3.38 Mn |
| Sep 30, 2022 | 2.76 Mn |
| Jun 30, 2022 | 6.53 Mn |
| Mar 31, 2022 | 257,000.00 |
| Dec 31, 2021 | 867,000.00 |
| Sep 30, 2021 | 868,000.00 |
| Mar 31, 2021 | 1.06 Mn |
| Dec 31, 2020 | 1.06 Mn |
| Sep 30, 2020 | 854,000.00 |
| Jun 30, 2020 | 1.58 Mn |
| Mar 31, 2020 | 8,707.00 |
| Dec 31, 2019 | 629,000.00 |
| Sep 30, 2019 | 5,726.00 |
| Jun 30, 2019 | 14,792.00 |
| Mar 31, 2019 | 3,330.00 |
| Dec 31, 2018 | 4,278.00 |
| Sep 30, 2018 | 4,403.00 |
| Jun 30, 2018 | 632.00 |
| Mar 31, 2018 | 52.00 |